United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 6.25 mg - carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [ see drug interactions ( 7.4) and clinical studies ( 14.1) ]. carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [ see   clinical studies ( 14.2) ]. carvedilol tablets are indicated for the management of essential hypertension [ see   clinical studies ( 14.3, 14.4)] . it can be used alone or in combination with other antihyper

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see drug interactions (7.4) , clinical studies (14.1)] . carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol tablets are contraindicated in the following conditions: risk summary available data regarding use of carvedilol in pregna

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization  [see  drug interactions (7.4) and clinical studies (14.1)] . carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) ( see clinical studies [14.2] ). carvedilol is indicated for the management of essential hypertension. ( see clinical studies [14.3, 14.4] ). it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics ( see drug interactions [7.2] ). carvedilol is contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status asthmaticus have been reported follo

United States - English - NLM (National Library of Medicine)

nucare pharmaceutical, inc. - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 25 mg - carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see  drug interactions (7.4) and clinical studies (14.1) ] . carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol tablets are contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 6.25 mg - carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see  drug interactions (7.4) and clinical studies (14.1) ] . carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol tablets are contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions.

United States - English - NLM (National Library of Medicine)

st marys medical park pharmacy - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets, usp are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets, usp are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)]. carvedilol tablets are contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status asthmaticus have been reported following single doses of carvedilol tablets. - second- or third-degree av block - sick sinus syndrome - severe bradycardia (unless a permanent pacemaker is in place) - patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy

United States - English - NLM (National Library of Medicine)

acetris health, llc - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see drug interactions (7.4) and clinical studies (14.1)]. carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . - carvedilol tablets are contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. death

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤ 40% (with or without symptomatic heart failure) [ see clinical studies(14.1) ] . carvedilol is indicated for the management of essential hypertension [ see clinical studies (14.2, 14.3)]. it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see  drug interactions (7.2) ]. carvedilol is contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status asthmaticus have been reported following single doses of carvedilol - second- or third-degree av block - sick sinus syndrome - severe bradycardia (unless a permanent pacemaker is in place) - patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. such patients should first be weaned fro

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets, usp are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) [see clinical studies (14.2) ]. carvedilol tablets, usp is indicated for the management of essential hypertension [see clinical studies (14.3) ]. it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2) ]. carvedilol is contraindicated in the following conditions: pregnancy category c. studies performed in pregnant rats and rabbits given carvedilol revealed increased post-implantation loss in rats at doses of 300 mg/kg/day (50 times the maximum recommended human dose [mrhd] as mg/m2 ) and in rabbits at doses of 75 mg/kg/day (25 times the mrhd as mg/m2 ). in the rats, there was also a decrease in fetal body weight at the maternally toxic dose of 300 mg/kg/day (50 times the

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see drug interactions (7.4), clinical studies (14.1)] . carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol tablets are contraindicated in the following conditions: available data regarding use of carvedilol tablets in pregnant women are insufficient to determine whether there are drug-associated risks of adverse developmental outcomes. there are risks to the mother and fetus associated with poorly controlled hypertension in pregnancy. the use of beta blockers during the third trimester of pregnancy may increase the risk of hypotension, bradycardia, hypoglycemia, and respiratory depression in the neonate [see clinical considerations] . in animal reproduction studies, there was no evidence of adverse developmental outcomes at clinically relevant doses [see data] . oral administration of carvedilol to pregnant rats during organogenesis resulted in post-implantation loss, decreased fetal body weight, and an increased frequency of delayed fetal skeletal development at maternally toxic doses that were 50 times the maximum recommended human dose (mrhd). in addition, oral administration of carvedilol to pregnant rabbits during organogenesis resulted in increased post-implantation loss at doses 25 times the mrhd [see data]. the estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section and post-partum hemorrhage). hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. pregnant women with hypertension should be carefully monitored and managed accordingly. neonates of women with hypertension who are treated with beta-blockers during the third trimester of pregnancy may be at increased risk for hypotension, bradycardia, hypoglycemia, and respiratory depression. observe newborns for symptoms of hypotension, bradycardia, hypoglycemia, and respiratory depression and manage accordingly. studies performed in rats and rabbits given carvedilol during fetal organogenesis revealed increased post-implantation loss in rats at a maternally toxic dose of 300 mg per kg per day (50 times the mrhd as mg per m2 ) and in rabbits (in the absence of maternal toxicity) at doses of 75 mg per kg per day (25 times the mrhd as mg per m2 ). in the rats, there was also a decrease in fetal body weight at 300 mg per kg per day (50 times the mrhd as mg per m2 ) accompanied by an increased incidence of fetuses with delayed skeletal development. in rats, the no-effect level for embryo-fetal toxicity was 60 mg per kg per day (10 times the mrhd as mg per m2 ); in rabbits, it was 15 mg per kg per day (5 times the mrhd as mg per m2 ). in a pre- and post-natal development study in rats administered carvedilol from late gestation through lactation, increased embryo-lethality was observed at a maternally toxic dose of 200 mg per kg per day (approximately 32 times the mrhd as mg per m2 ), and pup mortality and delays in physical growth/development were observed at 60 mg per kg per day (10 times the mrhd as mg per m2 ) in the absence of maternal toxicity. the no-effect level was 12 mg per kg per day (2 times the mrhd as mg per m2 ). carvedilol was present in fetal rat tissue. there are no data on the presence of carvedilol in human milk, the effects on the breastfed infant, or the effects on milk production. carvedilol is present in the milk of lactating rats. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for carvedilol tablets and any potential adverse effects on the breastfed infant from carvedilol tablets or from the underlying maternal condition. effectiveness of carvedilol tablets in patients younger than 18 years has not been established. in a double-blind trial, 161 children (mean age: 6 years; range: 2 months to 17 years; 45% younger than 2 years) with chronic heart failure [nyha class ii-iv, left ventricular ejection fraction less than 40% for children with a systemic left ventricle (lv), and moderate-severe ventricular dysfunction qualitatively by echo for those with a systemic ventricle that was not an lv] who were receiving standard background treatment were randomized to placebo or to 2 dose levels of carvedilol. these dose levels produced placebo-corrected heart rate reduction of 4 to 6 heart beats per minute, indicative of β-blockade activity. exposure appeared to be lower in pediatric subjects than adults. after 8 months of follow-up, there was no significant effect of treatment on clinical outcomes. adverse reactions in this trial that occurred in greater than 10% of subjects treated with carvedilol tablets and at twice the rate of placebo-treated subjects included chest pain (17% versus 6%), dizziness (13% versus 2%), and dyspnea (11% versus 0%). of the 765 subjects with heart failure randomized to carvedilol tablets in u.s. clinical trials, 31% (235) were aged 65 years or older, and 7.3% (56) were aged 75 years or older. of the 1,156 subjects randomized to carvedilol tablets in a long-term, placebo-controlled trial in severe heart failure, 47% (547) were aged 65 years or older, and 15% (174) were aged 75 years or older. of 3,025 subjects receiving carvedilol tablets in heart failure trials worldwide, 42% were aged 65 years or older. of the 975 subjects with myocardial infarction randomized to carvedilol tablets in the capricorn trial, 48% (468) were aged 65 years or older, and 11% (111) were aged 75 years or older. of the 2,065 hypertensive subjects in u.s. clinical trials of efficacy or safety who were treated with carvedilol tablets, 21% (436) were aged 65 years or older. of 3,722 subjects receiving carvedilol tablets in hypertension clinical trials conducted worldwide, 24% were aged 65 years or older. with the exception of dizziness in hypertensive subjects (incidence 8.8% in the elderly versus 6% in younger subjects), no overall differences in the safety or effectiveness (see figures 2 and 4) were observed between the older subjects and younger subjects in each of these populations. similarly, other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.